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Abstract
Metopimazine (MPZ) is an antiemetic considered as a currently used drug. In
France, it has become the leading antiemetic mediator due to its good tolerance,
however, its pharmacokinetics has never previously been studied in children.
MPZ was administered by oral route to 8 children with a single dose of 0.33 mg/
kg during an endocrine exploration using stimuli well known for its adverse eme-
tic effects. We used biological remnants from sera following an hGH test in order
to obtain the MPZ pharmacokinetics. Plasmatic concentrations of MPZ and the
active acid metabolite AMPZ, were quantified by HPLC-MS/MS during a
270 min test period. MPZ is quickly absorbed with a median Cmax of 17.2 ng/
mL at one hour and its half-life is 2.18 h. The plasmatic concentrations of AMPZ
were higher than MPZ with a median Cmax of 76.3 ng/mL, a Tmax to 150 min
and its concentration was approximately maintained at 50 ng/mL from 1 to 4 h.
The plasmatic concentrations in children are similar to those observed in adults.
No adverse effects, nausea or vomiting occurred during the trial. Therefore, these
results confirm the MPZ dosage that should be used in children under 15 kg
administered as 0.33 mg/kg up to 3 times a day.
Abbreviations
AMPZ, active metopimazine; API, atmospheric pressure ionization; AUC, area
under the curve; BMI, body mass index; CTD, common technical document; ESI,
electrospray ionization interface; hGH, human growth hormone; LOD, limit of
detection; LOQ, limit of quantification; MPZ, metopimazine; MRM, multiple reac-
tion monitoring.
Introduction
Metopimazine (MPZ) has been commercialized for the
past 30 years in France and is considered as a currently
used drug. This medication is frequently used to treat
nausea or vomiting especially during acute gastroenteritis.
It is a phenothiazine derivate which is an antidopaminer-
gic D2 receptor antagonist. In France, MPZ is sold under
various pharmaceutical forms. Hard capsules, supposito-
ries, injectable solutions and orodispersible tablets are
available for adults and a solution or suppositories for
children. Different drug administration routes can be cho-
sen to adapt the treatment to the patient’s requirements.
The transdermal route has been also studied but the low
percutaneous absorption of MPZ limits the development
of a transdermal form (Bounoure et al. 2008). The drug
only acts on area postrema receptors and peripheral recep-
tors due to its low brain penetration. Jolliet et al. (2007)
showed that MPZ brain penetration is lower than dom-
peridone and metoclopramide, as well as the main MPZ
metabolite, the acid metabolite AMPZ which also exhibits
a very low blood brain barrier permeability which
explains its good tolerance to MPZ.
MPZ is also a medication with a satisfactory therapeu-
tic balance. Herrstedt et al. (1997) reported the MPZ tol-
erance administered via the oral route at large doses in
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adults. These authors concluded that the tolerance
remained acceptable at a dose of 180 mg/day 30 mg 9 6
and at a higher dose, primary side effect was dizziness
caused by orthostatic hypotension.
The low brain penetration is thought to be the reason
why MPZ side effects are different from the other pheno-
thiazine compounds. The rare neurologic side effects are
sedation, drowsiness and extrapyramidal syndrome which
are reversible once the drug is stopped. This possible
extrapyramidal adverse event was reported by Herrstedt
et al. (1997) in a single patient with a very high dose of
360 mg per day. The a1 adrenergic antagonist activity
causes orthostatic hypotension and dizziness. MPZ is also
a low muscarinic cholinergic antagonist which can gener-
ate urine retention, visual disorder, constipation or dry
mouth (Herrstedt et al. 1993). These rare side effects are
described in the CTD.
Two recent notices from the French Drug Agency
(ANSM) on domperidone and metoclopramide MPZ
defined by default as the reference antiemetic medication
due to its good tolerance. Currently, metoclopramide is
contraindicated for children because of the high propor-
tion of major neurologic side effects such as extrapyrami-
dal syndrome (ANSM 2012). Also, the daily dose of
domperidone has been decreased for the elderly people
because of a risk of cardiac arrhythmia or sudden death
(ANSM 2011).
MPZ pharmacokinetics has been previously studied in
adults and a number of series have been reported in the
literature. For Herrstedt et al. (1996) the oral bioavail-
ability of MPZ was approximately 22.3%. This low value
is due to a liver deamination into MPZ acid. The oral
route only increases the area under the curve (AUC)
ratio between MPZ acid and MPZ, that is, 13.7 by oral
administration and 2.5 by intravenous administration.
For these authors the postprandial oral administration of
MPZ reduces the AUC of MPZ by 30% (Herrstedt et al.
1990).
Currently, to our knowledge, no study has been pub-
lished regarding MPZ pharmacokinetics in children. The
aim of this study was to validate the currently used pedi-
atric dosage of 0.33 mg/kg 3 times a day in children
under 15 kg.
Materials and Methods
Study population
The study was conducted within the framework of the
national constitution for organic collection. It received its
authorization from the Ministry of Higher Education and
Research and was registered under number 201161469
DC. The biological collection was obtained from organic
residues remaining after serum human growth hormone
(hGH) tests were performed for children explored in a
day hospital for assessment of their small size.
The organic residues obtained from these children were
used to perform a stimulation test for hGH secretion
using two stimuli, betaxolol and glucagon secretory
response and assessed over a 4 h period by repeated
blood sampling. As the test is known to cause nausea or
vomiting, this justified the oral administration of MPZ
30 min before starting the test. Biological collection
obtained from organic residues of this exploration of the
hGH secretion kinetics, permitted us to also assess the
kinetics of MPZ administered orally at the recommended
dose in children under 7 years of age.
Study design
Eight children explored at a day hospital for an evaluation
of their small size, were included in a biological collection
study. There were 4 boys and 4 girls, 2 to 6 years of age
with a body mass index (BMI) in kg/m2 which ranged
from 13.5 to 17.5 for boys and 13.7 to 17.9 for girls. After
individual child selection all parents received written
information regarding the study, and a signed informed
consent was obtained as recommended by the Committee
for the Protection of Individuals in the North West
Region of France.
A complete biological evaluation was conducted to assess
the children’s small size. The results confirmed a normal
liver and kidney function. The hGH secretion test protocol
results were as follows: Time minus 30 min, oral adminis-
tration of MPZ (Vogalene; Teva Laboratory, Courbevoie,
France) solution 0.1% at the recommended dosage for the
particular age, that is, standard pharmaceutical reference
found in the standard French pharmaceutical reference
manual common technical document (CTD), that is,
0.33 mg/kg, and a beta blocker (Kerlone or betaxolol
hydrochloride; Sanofi-Aventis, Paris, France) at a dose of
2.5 mg/kg (Herrstedt et al. 1990). Installation of the first
venous injection time 0 test administration by intravenous
injection of glucagon (i.e., Glucagen; Novo Nordisk La
De´fense - Paris, France) at a dose of 0.03 mg/kg.
Blood samples of 2 mL using a neutral tube as men-
tioned in this protocol for testing hGH secretion and
blood glucose, obtained via the venous route were per-
formed at 30, 0, +30, +90, +120, +150, +180, +240 min
and after a snack and control of blood glucose.
Blood samples were immediately sent to the laboratory
preserved in ice, centrifuged at 3600 G (4000rpm/min),
serum was kept frozen at 20°C until assayed for hGH
secretion. The residue recovered after serum dosage was
immediately refrozen at 20°C before the assay and its
metabolite MPZ. A maximum period of 3 months took
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place between the beginning the biological collection and
tests performed this series.
Chemicals and reagents
Methanol and acetonitrile, both HPLC gradient grade,
were purchased from VWR Chemicals (Fontenay-sous-
Bois, France). All other chemicals, formic acid (99%,
VWR Chemicals), ammonia solution (25%, Merck,
Darmstadt, Germany), ammonium formate (Fluka, Buchs,
Switzerland) were analytical grade. Deionized water was
purified using the Milli-Q-system from Millipore Corpo-
ration (Bedford, MA). Drug-free serum Liphochek was
purchased from Bio-Rad (Irvine, CA). MPZ and its acid
metabolite were obtained from Schwarz Pharma (Bou-
logne-Billancourt, France); stock solutions of each com-
pound were prepared at 1 mg/mL in methanol. Working
solutions of MPZ and acid metabolite at 10 lg/mL in
methanol and stored at +4°C, were used for standards
preparation in drug-free serum at the following levels: 1–
10–100 ng/mL. The limit of quantification (LOQ) and
the limit of detection (LOD) of this on-line analytical
method were, respectively, of 1 and 0.1 ng/mL. Zolpi-
dem-d6 was used as internal standard (LGC Standards,
Teddington, Middlesex, UK); a stock solution at 10 lg/
mL (stored at 20°C) and a working solution at 10 ng/
mL (stored at +4°C) were prepared in methanol.
HPLC-MS/MS system
The column-switching HPLC-MS/MS system consisted of
an 1525 Micro Binary Pump (pump 1 for washing sol-
vent; Waters, Milford, MA), an Alliance 2795 HPLC
pump (pump 2 for elution mobile phase; Waters), a sam-
ple injection valve with 100 lL sample loop (Rheodyne,
Cotati, CA), a 10-port valve allowing switching or direct
injection (valve 1; Rheodyne), a six-port switching valve
(valve 2; Rheodyne), and a Quattro MicroTM API tandem
mass spectrometer (Waters) equipped with an atmo-
spheric pressure ionization (API) electrospray ionization
interface (ESI) and controlled by computer through
MassLynx software (Version 4.2; WATERS SAS, Guyan-
court, France). The extraction column was an Oasis HLB
(2.1 9 20 mm; 25 lm, Waters). The reversed-phase ana-
lytical column was an Atlantis C18 (2.1 9 150 mm;
3 lm, Waters). The wash solvent for sample extraction
and enrichment, delivered by pump 1 at 2 mL/min, was
Milli-Q water fortified with 0.2% ammonia. The mobile
phase for sample elution and separation, delivered by
pump 2 at 0.3 mL/min, consisted of 20 mmol/L ammo-
nium formate aqueous solution adjusted to pH 2.8 with
formic acid (solvent A) and acetonitrile/solvent A (90:10,
v/v) [solvent B]. Analysis cycle time including solid phase
extraction and chromatographic separation was 6 min.
Detection was operated in positive ionization mode. The
probe capillary voltage was 3.2 kV; the source block and
desolvation temperatures were 120°C and 450°C, respec-
tively. Cone voltages, collision energies, as precursor and
product ion transitions, optimized for MPZ and its metab-
olites, and zolpidem-d6 are presented in Table 1. Quanti-
tative measurements were carried out by HPLC-MS/MS in
the multiple reaction monitoring (MRM) mode.
Sample preparation
100 lL of serum was diluted to 1:200 in water and zolpi-
dem-d6 solution was added with final concentration of
1 ng/mL. After vortex-mixed, 100 lL of the mixture were
injected in the on-line HPLC-MS/MS system.
Clinical study
Pharmacokinetic assessment
Pharmacokinetic study was conducted on PK Solution
Software (Summit Research Services, Montrose, CO) using
a separate system to determine the main pharmacokinetics
parameters of MPZ. These parameters were calculated
using the median concentration. Pharmacokinetic model-
ing is performed using a noncompartmental method. The
AUC∞ is determined by trapezoid rule. Cmax is the maxi-
mum observed concentration (from data) and Tmax is the
time at maximum observed concentration. The half time is
the time required for the concentration to diminish by
one-half obtained from first-order kinetics on elimination
phase. Clearance and Vd are based on the AUC.
The method was validated over the concentration range
of 5–500 ng/mL for MPZ and AMPZ. The LOD evaluated
over three runs with duplicates from three different
samples and defined as the lowest concentration
Table 1. HPLC-MS/MS parameters for metopimazine and its metabo-
lites, and internal standard (zolpidem-d6).
Molecule
Precursor
(m/z)
Production
(m/z)
Cone
voltage (V)
Collision
energy (eV)
Metopimazine 446.1 141.0 42 36
446.1 126.0 42 28
446.1 169.1 42 28
Acid metabolite 447.1 142.0 42 38
447.1 170.1 42 26
447.1 98.9 42 56
Sulfoxide
metabolite
462.1 69.8 40 42
462.1 98.0 40 28
462.1 141.2 40 28
Zolpidem-d6 314.3 263.2 45 28
Bold indicates quantification.
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producing a peak eluting within 0.1 min of analyte
retention time for the lowest calibrator with signal-to-
noise ≥3:1 was 1 ng/mL for MPZ and 1.5 ng/mL for
AMPZ. The LOQ also evaluated in the same manner, and
defined as the lowest concentration that met LOD criteria
with signal-to-noise ≥10:1 was 5 ng/mL for MPZ and
7 ng/mL for AMPZ. The intra- and inter-day precision of
the method at three concentrations were 1.0–4.6% and
1.6–5.8% for MPZ and 1.2–5.1% and 1.9–7.0% for AMPZ
while the intra- and inter-day % accuracy were 99.0–
93.8% and 101.8–107.0% for MPZ.
The stability of these compounds was established in a
series of stability studies. A drug-free plasma pool was
spiked with MPZ and AMPZ at three different concentra-
tions (10–30–60 ng/mL and 20–75–150 ng/mL). The
pools were kept at 20°C and analyzed after three peri-
ods, 1, 2, and 3 months. All the results ranged between
89% and 107%. The stability data show that there were
no stability-related issues that might cause problems to
the PK study.
Results
Children received a single dose of 0.33 mg/kg of MPZ
by oral route according the recommended dose of the
CTD. The MPZ median pharmacokinetics parameters
are shown in Table 2. MPZ given by oral route is
quickly absorbed with a Tmax of 1 h and Cmax 17.2 ng/
mL (6.4–92.2). The half time was 2.18 h with a clear-
ance of 86 mL/min and a distribution volume of
16.28 L. The plasmatic concentrations of MPZ for each
child are shown in Figure 1. These plasmatic concentra-
tions seem to be close to concentrations in adults. The
comparison between the MPZ pharmacokinetic parame-
ters in adults and children is shown in Table 3. Herr-
stedt et al. (1990) showed that the median Cmax was
43 ng/mL [14–69] for an oral dose of 20 mg and 59 ng/
mL [28; 182] for an oral dose of 40 mg. The doses used
by Herrstedt et al. are higher than the CTD which rec-
ommends a dose ranging from 15 to 30 mg per day in
one or two doses.
MPZ is metabolized by the liver into MPZ acid. This
active metabolite appears at the same time as MPZ due
to a first pass metabolism. AMPZ plasmatic concentra-
tions for each child are represented in Figure 2. The
Table 2. Median pharmacokinetic parameters of metopimazine in
children (n = 8).
Tmax Cmax Half time Clearance
Volume of
distribution
MPZ 60 min 17.2 ng/mL 2.18 h 86 mL/min 16.28 L
Median pharmacokinetic parameters of metopimazine in children
(n = 8).
Figure 1. Plasmatic concentration of metopimazine in eight children.
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AMPZ plasmatic concentrations are higher than MPZ
with a median Cmax of 73.6 ng/mL [range 36.9–145.7]
and a Tmax to 150 min. The ratio of Cmax AMPZ/MPZ is
4.28. These results are in agreement with the study
reported by Herrstedt et al. (1990). After a preprandial
oral dose of 20 mg, these authors observed a Tmax of
120 min, a median Cmax of 107.5 ng/mL for AMPZ and a
Cmax ratio of 1.72. They found a wide range between
MPZ and AMPZ serum concentrations. Also, they were
higher than the concentrations generally found due to the
use of a higher dose rather than that recommended in the
CTD. Also, the MPZ and AMPZ concentrations were
higher. This result is in accordance with data published in
the literature. Herrstedt et al. (1990) also reported a
highly significant interindividual variation in MPZ AUC.
Discussion
Due to AMPZ pharmacokinetics a single or double dose per
day by oral route is possible in adults. Herrsted et al. showed
that after a MPZ administration of 40 mg in six healthy vol-
unteers, the median AMPZ Cmax of 296 ng/mL was obtained
after a Tmax of 120 min. The mean concentration of AMPZ
was always close to 70 ng/mL after 8 h. Moreover, after 8 h,
the mean MPZ concentration was not detectable according to
the MPZ half-life -time, that is, 2.18 h in this study. There-
fore, the extended antiemetic activity was due to the AMPZ.
The AMPZ half-life time could not be determined due to the
insufficient amount of time available for the study. However,
nevertheless AMPZ appears to have a greater half-life -time
compared to MPZ and produced by MPZ deamination The
AMPZ concentration appeared to be stable during the initial
four hours of the trial. In Figure 3, the mean AMPZ concen-
tration was maintained at approximately 50 ng/mL from 1 to
4 h of the study time. AMPZ may also explain the good toler-
ance of MPZ. Also, MPZ has the lowest brain penetration of
any antiemetic drug as compared to domperidone or meto-
clopramide. Jolliet et al. (2007) assessed the endothelial per-
meability of MPZ and AMPZ and showed that AMPZ has an
Table 3. Comparison of median PK parameters between children
and adults.
Adults (Herrstedt
et al. 1990) Children
Dose 20 mg in a single
oral administration
0.33 mg/kg
in a single oral
administration
Median MPZ Cmax 43 ng/mL 17.2 ng/mL
Median MPZ Tmax 52 min 1 h
Median AMPZ Cmax 107.5 ng/mL 73.6 ng/mL
Median AMPZ Cmax 2 h 2 h 30 min
Figure 2. Plasmatic concentration of metopimazine in eight children.
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endothelial permeability of 0.49 9 103 cm min1
compared to 9.35 9 103 cm min1 for MPZ, 44.9 9 103
cm min1 for domperidone.
hGH endocrine investigation
During this trial, children received a large dose of gluca-
gon, the stimuli used for hGH endocrine exploration
which provokes nausea or vomiting. The administration of
glucagon is known to induce nausea and to be emesis. Dill-
man et al. (2013) showed that after a glucagon IV admin-
istration in 50 children, 48% self-reported nausea and 8%
experienced emesis (Colle et al. 1984). In this study, no
adverse reaction, nausea or emesis was observed with an
MPZ administration of 0.33 mg/kg although nausea reac-
tions were expected in four children. During the hGH
stimulation tests, at an administered dosage of 0.33 mg/kg,
we were able to obtain the MPZ and AMPZ serum concen-
tration of approximately 10 and 50 ng/mL with important
videral variations. No nausea or emesis was observed in
any of the eight children studied. However, as we did not
use a control group we cannot consider, with certainty,
these serum concentrations as being representative of an
active concentration. Nevertheless, the results we obtained
corresponded to the dosage considered to be effective and
considered as a currently used drug, that is, 0.33 mg/kg
and according the recommended dose of the CTD. No
children tested had growth hormone deficiency.
Conclusion
In France, MPZ is now the recommended antiemitic espe-
cially in children due to its good tolerance. Pharmacokinet-
ics in children was unknown prior to this study and the
results were similar as compared to adults. The original
pharmacokinetics presented in this paper corresponds to
the posology per os considered as a currently used drug as
being useful and effective in children. Our results are in
accordance with the recommended MPZ dosage for chil-
dren under 15 kg of 0.33 mg/kg with up to three adminis-
trations per day. Also it can be considered that the
common technical document recommended therapeutic
dosage can be adapted for children under 15 kg weight.
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